mbiomics

About mbiomics

mbiomics designs and develops complex microbiome-based therapeutics to change the treatment paradigm for severe and chronic diseases. By combining proprietary precision analytics with patient insights, the company builds pipelines of rationally selected microbial communities for indication-specific treatment, aiming to leverage the gut microbiome’s immunological and metabolic potential to restore healthy ecosystems and overcome disease. The team focuses on safety, efficacy, and tailored disease-targeting properties through advanced analytical methods to inform microbial strain selection. The company has a presence in Germany (Neuried) and the United States (Boston) as part of its international operations.